Journal of Antimicrobial Chemotherapy 2025

3 papers
The 2025 edition of the Journal of Antimicrobial Chemotherapy includes research addressing the clinical challenges of antibiotic resistance and the safety profiles of long-term antimicrobial therapies. A primary focus is placed on the resistance mechanisms and clinical efficacy of tigecycline against Klebsiella pneumoniae, reflecting ongoing efforts to manage multidrug-resistant pathogens. Additionally, the journal examines clinical outcomes and treatment modalities for carbapenem-resistant Enterobacteriaceae (CRE) bloodstream infections in pediatric populations. Safety monitoring remains a central theme, with documentation of adverse effects such as peripheral neuropathy during extended suppressive therapy with tedizolid. Contributions from authors such as Abdulrahman Hashim, Agathe Becker, and Agnès Henry highlight a focus on refining therapeutic regimens and understanding the long-term impacts of specific antimicrobial agents. These studies collectively contribute to the literature on antimicrobial stewardship, resistance patterns, and the management of complex bacterial infections in diverse patient groups.

Top Authors

AuthorPapers
Jean Baptiste Masson1

Papers

Title
Comment on: Clinical outcomes and the impact of treatment modalities in children with carbapenem-resistant Enterobacteriaceae bloodstream infections: a retrospective cohort study from a tertiary unive
Peripheral neuropathy during long-term suppressive therapy with tedizolid: a case series
Research progress on resistance mechanisms and clinical efficacy of tigecycline against Klebsiella pneumoniae